Background COVID-19 can cause profound inflammation and coagulopathy, and while
many mechanisms have been proposed, there is no known common pathway leading to a …

Background The COVID-19 pandemic has highlighted the potentially lethal consequences
of cross-talk between coagulation, inflammation and innate immune processes. Hospitalised …

Several studies shed light on the interplay among inflammation, thrombosis, multi-organ
failures and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection …

Objectives Pulmonary thrombus formation is a hallmark of coronavirus disease 2019
(COVID-19). A dysregulated immune response culminating in thromboinflammation has …

Coagulopathy in severe COVID-19 is common but poorly understood. The purpose of this
study was to determine how SARS-CoV-2 infection impacts histone levels, fibrin structure …

Circulating histones have been suggested as critical mediators and potential
diagnostic/prognostic markers in several hyperinflammatory diseases, including Sars-CoV-2 …

Letters to the Editor [11.2-60.0] vs. 8.6 µg/ml [3.1-24.8], P= 0.002), and, accordingly, patients
with histones> 30 μg/mL were more likely to die (13/29 [44.8%] vs. 12/84 [14.3%], P= 0.001) …

Severe COVID-19 is frequently associated with thromboembolic complications. Increased
platelet activation and platelet–leukocyte aggregate formation can amplify thrombotic …

The infectious respiratory condition COVID-19 manifests a clinical course ranging from
mild/moderate up-to critical systemic dysfunction and death linked to thromboinflammation …

Abnormal coagulation dynamics, including disseminated intravascular coagulopathy,
pulmonary embolism, venous thromboembolism and risk of thrombosis are often associated …